Abstract
2-Amino-6-fluoro-9-(4-hydroxy-3-hydroxymethylbut-1-yl)purine (7), and its mono- and diesters 8-15 were prepared and evaluated for their potential as prodrugs of penciclovir. Treatment of 2-amino-6-chloro-9-(4-hydroxy-3-hydroxymethylbut-1-yl)purine (5) with trimethylamine in THF followed by a reaction of the resulting trimethylammonium chloride salt 6 with KF in DMF afforded 2-amino-6-fluoro-9-(4-hydroxy-3-hydroxymethylbut-1-yl)purine (7) in 80% yield. Esterification of 7 with an appropriate acid anhydride [Ac2O, (EtCO)2O, (n-PrCO)2O, or (i-PrCO)2O] in DMF in the presence of a catalytic amount of DMAP produced the mono-esters 8-11 in 42-45% yields and diesters 12-15 in 87-99% yields. Of the prodrugs tested in rats, the mono-isobutyrate 11 was the most efficiently absorbed and metabolized to 7, showing the mean maximum total concentration of penciclovir (5.5μg/mL) and 7 (10.8μg/mL) in the blood was much higher than the mean maximum concentration of penciclovir (11.5μg/mL) from famciclovir. However, the mean concentrations of penciclovir from 11 were lower than those from famciclovir because of the limited conversion of a major metabolite 7 to penciclovir by adenosine deaminase. Copyright (C) 1999 Elsevier Science Ltd.
Original language | English |
---|---|
Pages (from-to) | 565-570 |
Number of pages | 6 |
Journal | Bioorganic and Medicinal Chemistry |
Volume | 7 |
Issue number | 3 |
DOIs | |
State | Published - Mar 1999 |
Keywords
- Antivirals
- Chemotherapy
- Enzyme inhibitors
- Nucleosides